Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020

Gidding, HF; Machalek, DA; Hendry, AJ; Quinn, HE; Vette, K; Beard, FH; Shilling, HS; Hirani, R; Gosbell, IB; Irving, DO; Hueston, L; Downes, M; Carlin, JB; O'Sullivan, MV; Dwyer, DE; Kaldor, JM; Macartney, K

Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020

Gidding, HF Machalek, DA Hendry, AJ Quinn, HE Vette, K Beard, FH Shilling, HS Hirani, R Gosbell, IB Irving, DO Hueston, L Downes, M Carlin, JB O'Sullivan, MV Dwyer, DE Kaldor, JM Macartney, K

Permalink

Publisher:: AMPCo
Publication Type:: Journal Article
Citation:: The Medical Journal of Australia, 2021, 214, (4), pp. 179-185
Issue Date:: 2021-02-03

Closed Access

	Filename	Description	Size
	Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020.pdf	Published version	533.67 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Gidding, HF
dc.contributor.author	Machalek, DA
dc.contributor.author	Hendry, AJ
dc.contributor.author	Quinn, HE
dc.contributor.author	Vette, K
dc.contributor.author	Beard, FH
dc.contributor.author	Shilling, HS
dc.contributor.author	Hirani, R
dc.contributor.author	Gosbell, IB
dc.contributor.author	Irving, DO
dc.contributor.author	Hueston, L
dc.contributor.author	Downes, M
dc.contributor.author	Carlin, JB
dc.contributor.author	O'Sullivan, MV
dc.contributor.author	Dwyer, DE
dc.contributor.author	Kaldor, JM
dc.contributor.author	Macartney, K
dc.date.accessioned	2022-04-27T08:15:17Z
dc.date.available	2020-12-21
dc.date.available	2022-04-27T08:15:17Z
dc.date.issued	2021-02-03
dc.identifier.citation	The Medical Journal of Australia, 2021, 214, (4), pp. 179-185
dc.identifier.issn	0025-729X
dc.identifier.issn	1326-5377
dc.identifier.uri	http://hdl.handle.net/10453/156672
dc.description.abstract	OBJECTIVES: To estimate SARS-CoV-2-specific antibody seroprevalence after the first epidemic wave of coronavirus disease 2019 (COVID-19) in Sydney. SETTING, PARTICIPANTS: People of any age who had provided blood for testing at selected diagnostic pathology services (general pathology); pregnant women aged 20-39 years who had received routine antenatal screening; and Australian Red Cross Lifeblood plasmapheresis donors aged 20-69 years. DESIGN: Cross-sectional study; testing of de-identified residual blood specimens collected during 20 April - 2 June 2020. MAIN OUTCOME MEASURE: Estimated proportions of people seropositive for anti-SARS-CoV-2-specific IgG, adjusted for test sensitivity and specificity. RESULTS: Thirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; antenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548); there were no clear patterns by age group, sex, or location of residence. Adjusted estimated seroprevalence among people who had had general pathology blood tests (all ages) was 0.15% (95% credible interval [CrI], 0.04-0.41%), and 0.29% (95% CrI, 0.04-0.75%) for plasmapheresis donors (20-69 years). Among 20-39-year-old people, the age group common to all three collection groups, adjusted estimated seroprevalence was 0.24% (95% CrI, 0.04-0.80%) for the general pathology group, 0.79% (95% CrI, 0.04-1.88%) for the antenatal screening group, and 0.69% (95% CrI, 0.04-1.59%) for plasmapheresis donors. CONCLUSIONS: Estimated SARS-CoV-2 seroprevalence was below 1%, indicating that community transmission was low during the first COVID-19 epidemic wave in Sydney. These findings suggest that early control of the spread of COVID-19 was successful, but efforts to reduce further transmission remain important.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	AMPCo
dc.relation.ispartof	The Medical Journal of Australia
dc.relation.isbasedon	10.5694/mja2.50940
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	General & Internal Medicine
dc.subject.mesh	Adolescent
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	Australia
dc.subject.mesh	Blood Donors
dc.subject.mesh	COVID-19
dc.subject.mesh	Child
dc.subject.mesh	Child, Preschool
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Immunoglobulin G
dc.subject.mesh	Infant
dc.subject.mesh	Infant, Newborn
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	Pandemics
dc.subject.mesh	Pregnancy
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Seroepidemiologic Studies
dc.subject.mesh	Young Adult
dc.subject.mesh	Humans
dc.subject.mesh	Immunoglobulin G
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Seroepidemiologic Studies
dc.subject.mesh	Pregnancy
dc.subject.mesh	Adolescent
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Child
dc.subject.mesh	Child, Preschool
dc.subject.mesh	Infant
dc.subject.mesh	Infant, Newborn
dc.subject.mesh	Blood Donors
dc.subject.mesh	Australia
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Young Adult
dc.subject.mesh	Pandemics
dc.subject.mesh	COVID-19
dc.subject.mesh	SARS-CoV-2
dc.title	Seroprevalence of SARS‐CoV‐2‐specific antibodies in Sydney after the first epidemic wave of 2020
dc.type	Journal Article
utslib.citation.volume	214
utslib.location.activity	Australia
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2022-04-27T08:15:14Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	214
utslib.citation.issue	4

Abstract:

OBJECTIVES: To estimate SARS-CoV-2-specific antibody seroprevalence after the first epidemic wave of coronavirus disease 2019 (COVID-19) in Sydney. SETTING, PARTICIPANTS: People of any age who had provided blood for testing at selected diagnostic pathology services (general pathology); pregnant women aged 20-39 years who had received routine antenatal screening; and Australian Red Cross Lifeblood plasmapheresis donors aged 20-69 years. DESIGN: Cross-sectional study; testing of de-identified residual blood specimens collected during 20 April - 2 June 2020. MAIN OUTCOME MEASURE: Estimated proportions of people seropositive for anti-SARS-CoV-2-specific IgG, adjusted for test sensitivity and specificity. RESULTS: Thirty-eight of 5339 specimens were IgG-positive (general pathology, 19 of 3231; antenatal screening, 7 of 560; plasmapheresis donors, 12 of 1548); there were no clear patterns by age group, sex, or location of residence. Adjusted estimated seroprevalence among people who had had general pathology blood tests (all ages) was 0.15% (95% credible interval [CrI], 0.04-0.41%), and 0.29% (95% CrI, 0.04-0.75%) for plasmapheresis donors (20-69 years). Among 20-39-year-old people, the age group common to all three collection groups, adjusted estimated seroprevalence was 0.24% (95% CrI, 0.04-0.80%) for the general pathology group, 0.79% (95% CrI, 0.04-1.88%) for the antenatal screening group, and 0.69% (95% CrI, 0.04-1.59%) for plasmapheresis donors. CONCLUSIONS: Estimated SARS-CoV-2 seroprevalence was below 1%, indicating that community transmission was low during the first COVID-19 epidemic wave in Sydney. These findings suggest that early control of the spread of COVID-19 was successful, but efforts to reduce further transmission remain important.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/156672